If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
